Log in

Relevant bibliographies by topics / Individualized treatment regime / Journal articles

To see the other types of publications on this topic, follow the link: Individualized treatment regime.

Journal articles on the topic 'Individualized treatment regime'

Author: Grafiati

Published: 23 November 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Individualized treatment regime.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

최영근. "Individualized Treatment Regime for Personalized Medicine: A Review." Quantitative Bio-Science 36, no. 1 (2017): 7–13. http://dx.doi.org/10.22283/qbs.2017.36.1.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Huang, Xinyang, Yair Goldberg, and Jin Xu. "Multicategory individualized treatment regime using outcome weighted learning." Biometrics 75, no. 4 (2019): 1216–27. http://dx.doi.org/10.1111/biom.13084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Marques, Lara, and Nuno Vale. "Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients." Pharmaceutics 17, no. 1 (2024): 39. https://doi.org/10.3390/pharmaceutics17010039.

Full text

Abstract:

Background: Salbutamol, a short-acting β2-agonist used in asthma treatment, is available in multiple formulations, including inhalers, nebulizers, oral tablets, and intravenous, intramuscular, and subcutaneous routes. Each formulation exhibits distinct pharmacokinetic (PK) and pharmacodynamic (PD) profiles, influencing therapeutic outcomes and adverse effects. Although asthma management predominantly relies on inhaled salbutamol, understanding how these formulations interact with patient-specific characteristics could improve personalized medicine approaches, potentially uncovering the therape

APA, Harvard, Vancouver, ISO, and other styles

4

Feshchenko, Yu I., N. A. Litvinenko, N. V. Grankina, et al. "Treatment of patients with multidrugresistant and extensively drug resistant tuberculosis depending on the composition of individualized regimens: immediate and longterm results." Tuberculosis, Lung Diseases, HIV Infection, no. 4 (December 15, 2021): 7–15. http://dx.doi.org/10.30978/tb2021-4-7.

Full text

Abstract:

Objective — to study the effectiveness of treatment of MDR-TB (multidrug-resistant tuberculosis) and preXDR-TB/XDR-TB (pre-extensively and extensively drug resistant tuberculosis), depending on the composition of ITRs (individualized treatment regimens). Materials and methods. Тhe prospective observational study included 566 patients with MDR/preXDR-TB and XDR-TB during 2016—2020 on the scientific clinical bases of the SI «National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine» and ME «Kryvyi Rih Anti-tuberculosis Dispensary» Dnipropetrovsk Regional

APA, Harvard, Vancouver, ISO, and other styles

5

Frommeyer, Timothy C., Michael M. Gilbert, Reid M. Fursmidt, et al. "Reinforcement Learning and Its Clinical Applications Within Healthcare: A Systematic Review of Precision Medicine and Dynamic Treatment Regimes." Healthcare 13, no. 14 (2025): 1752. https://doi.org/10.3390/healthcare13141752.

Full text

Abstract:

Background/Objectives: Reinforcement learning (RL), a subset of machine learning, has emerged as a promising tool for supporting precision medicine and dynamic treatment regimes by enabling adaptive, data-driven clinical decision making. Despite its potential, challenges such as interpretability, reward definition, data limitations, and clinician adoption remain. This review aims to evaluate the recent advancements in RL in precision medicine and dynamic treatment regimes, highlight clinical fields of application, and propose practical frameworks for future integration into medical practice. M

APA, Harvard, Vancouver, ISO, and other styles

6

Rich, Benjamin, Erica E. M. Moodie, and David A. Stephens. "Influence Re-weighted G-Estimation." International Journal of Biostatistics 12, no. 1 (2016): 157–77. http://dx.doi.org/10.1515/ijb-2015-0015.

Full text

Abstract:

Abstract Individualized medicine is an area that is growing, both in clinical and statistical settings, where in the latter, personalized treatment strategies are often referred to as dynamic treatment regimens. Estimation of the optimal dynamic treatment regime has focused primarily on semi-parametric approaches, some of which are said to be doubly robust in that they give rise to consistent estimators provided at least one of two models is correctly specified. In particular, the locally efficient doubly robust g-estimation is robust to misspecification of the treatment-free outcome model so

APA, Harvard, Vancouver, ISO, and other styles

7

Olivieri, Martin, Christoph Königs, Christine Heller, et al. "Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany." Hämostaseologie 39, no. 04 (2019): 355–59. http://dx.doi.org/10.1055/s-0039-1677874.

Full text

Abstract:

AbstractSimilar to the general population, overweight and obesity have increasingly become a medical and economic burden also in patients with haemophilia in industrialized nations. In this study in seven German haemophilia centres, we identified a prevalence of overweight and obesity of 25.2% among 254 young patients <30 years (median: 13 years; range: 0–30 years) with severe haemophilia A and without a history of inhibitors. The median FVIII dosage based on bodyweight was significantly higher in normal weight compared with overweight or obese patients (96.9 vs. 72.9 IU/kg/week, respective

APA, Harvard, Vancouver, ISO, and other styles

8

Bidu, Nadielle S., Bruno J. D. Fernandes, Eduardo J. C. Dias, et al. "Vancomycin Therapeutic Regime Adjustment in Newborns and Infants with Bacterial Infection: Case Series." Current Pharmaceutical Biotechnology 20, no. 4 (2019): 346–51. http://dx.doi.org/10.2174/1389201020666190319161511.

Full text

Abstract:

Background: Vancomycin is used mostly to overcome infections caused by methicillinresistant microorganisms. There are no well-established administration protocols for neonates and infants, so the leak of a specific administration regime in that population may lead to serum concentrations beyond the specified range. Objective: This case series evaluated the pharmacokinetics adjustment from a vancomycin therapeutic regimen prescribed to neonates and infants with bacterial infection at a neonatal public hospital intensive- care-unit, with the primary purpose to verify cases of nephrotoxicity. Met

APA, Harvard, Vancouver, ISO, and other styles

9

Hoffmann, Christian, Toke Ringbaek, Anja Eckstein, et al. "Long-Term Follow-Up of Patients with Conjunctival Lymphoma after Individualized Lens-Sparing Electron Radiotherapy: Results from a Longitudinal Study." Cancers 15, no. 22 (2023): 5433. http://dx.doi.org/10.3390/cancers15225433.

Full text

Abstract:

Irradiation with electrons is the primary treatment regime for localized conjunctival low-grade lymphomas. However, radiation-induced cataracts are a major cause of treatment-related morbidity. This study investigates whether lens-sparing electron irradiation produces sufficient disease control rates while preventing cataract formation. All consecutive patients with strictly conjunctival, low-grade Ann Arbor stage IE lymphoma treated with superficial electron irradiation between 1999 and 2021 at our department were reviewed. A total of 56 patients with 65 treated eyes were enrolled with a medi

APA, Harvard, Vancouver, ISO, and other styles

10

Zhang, Jianzhong, ChaoZhao Liang, Xuejun Shang, and Hongjun Li. "Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom? Current Perspectives on Diagnosis, Treatment, and Prognosis." American Journal of Men's Health 14, no. 1 (2020): 155798832090320. http://dx.doi.org/10.1177/1557988320903200.

Full text

Abstract:

Definitive diagnosis and selection of effective treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) are frustrations encountered frequently by urology care providers in their practice. Knowledge of etiology and pathophysiology is not sufficient and therapeutic guidelines have not yielded acceptable outcomes and prognoses for both patients and care providers. The authors present updated perspectives on CP/CPPS, including definition, diagnosis, treatment, and prognosis, based on literature review and clinical experience. A key point is to shift the diagnostic and therapeutic

APA, Harvard, Vancouver, ISO, and other styles

11

Fernández-Castillejo, Sara, Joan Badia, Luís de la Cruz-Merino, et al. "Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial." Cancers 17, no. 3 (2025): 532. https://doi.org/10.3390/cancers17030532.

Full text

Abstract:

Background: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for high-dose chemotherapy have limited treatment options and poor life expectancy. The purpose of this study is to identify a serum metabolomic profile that may be predictive of outcome in patients with R/R-DLBCL. Methods: This study included 69 R/R DLBCL patients from the R2-GDP-GOTEL trial (EudraCT 2014-001620-299). Serum samples were collected at baseline, and the mean length of follow-up was 41 months. Serum metabolites were analyzed by nuclear magnetic resonance (NMR). Metaboli

APA, Harvard, Vancouver, ISO, and other styles

12

Frelick, Bill. "What’s Wrong with Temporary Protected Status and How to Fix It: Exploring a Complementary Protection Regime." Journal on Migration and Human Security 8, no. 1 (2020): 42–53. http://dx.doi.org/10.1177/2331502419901266.

Full text

Abstract:

Executive Summary Temporary Protected Status (TPS) became part of the US protection regime in 1990 to expand protection beyond what had been available under the US Refugee Act of 1980, which had limited asylum to those who met the refugee definition from the United Nations’ 1951 Refugee Convention. The TPS statute authorized the attorney general to designate foreign countries for TPS based on armed conflict, environmental disasters, and other extraordinary and temporary conditions that prevent designated nationals from returning in safety. While providing blanket protection that very likely ha

APA, Harvard, Vancouver, ISO, and other styles

13

Ranade, Manjiri Anil. "Ayurgenomics – A narrative review." BLDE University Journal of Health Sciences 9, no. 1 (2024): 91–94. http://dx.doi.org/10.4103/bjhs.bjhs_169_23.

Full text

Abstract:

Abstract: Ayurgenomics is the integration of Ayurvedic principles with genomics to provide personalized approaches for the predictive, preventive, and curative aspects of medicine. It focuses on the interindividual variability due to genetic variability in humans, using the concept of Prakriti, which is a fusion of the comparative proportion of three main things, i.e., Tridoshas, namely, Vata, Pitta, and Kapha. Prakriti is used to define physical, physiological, and psychological traits of an individual and is the template for individualized diet, lifestyle counseling, and treatment. Ayurgenom

APA, Harvard, Vancouver, ISO, and other styles

14

Scheetz, J. S., G. S. Morris, K. E. Brueilly, E. A. Brannan, and E. Del Fabbro. "Effects of glucocorticoid treatment on the functional capacity of stem cell transplant recipients entering a rehabilitation program." Journal of Clinical Oncology 27, no. 15_suppl (2009): 7104. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.7104.

Full text

Abstract:

7104 Background: Emerging data strongly supports the concept that stem cell transplant (SCT) recipients derive psychological and physiological benefit from participation in exercise training programs. Many SCT recipients receive glucocorticoids (GC) for prolonged periods, increasing their risk for proximal muscle damage and raising the possibility that SCT recipients on GC may differ from those SCT recipients not receiving GC in terms of their exercise/functional capacity. This becomes an important reconditioning issue because exercise prescription and progression is predicated on initial exer

APA, Harvard, Vancouver, ISO, and other styles

15

Nguyen, Crystal T., Daniel J. Luckett, Anna R. Kahkoska, et al. "Estimating individualized treatment regimes from crossover designs." Biometrics 76, no. 3 (2019): 778–88. http://dx.doi.org/10.1111/biom.13186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Laber, E. B., and Y. Q. Zhao. "Tree-based methods for individualized treatment regimes." Biometrika 102, no. 3 (2015): 501–14. http://dx.doi.org/10.1093/biomet/asv028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Laber, Eric B., and Ana-Maria Staicu. "Functional Feature Construction for Individualized Treatment Regimes." Journal of the American Statistical Association 113, no. 523 (2018): 1219–27. http://dx.doi.org/10.1080/01621459.2017.1321545.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Yang, Huiyu, Jiangang Zhang, Ying Shan, et al. "Patient-derived 3D bioprinting pan-cancer drug screening platform for personalized medicine." Journal of Clinical Oncology 42, no. 16_suppl (2024): e15088-e15088. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15088.

Full text

Abstract:

e15088 Background: Patient-derived tumor model offers an individualized approach to overcome interpatient heterogeneity in cancer therapy. 3D bioprinting (3DB) enables construction of in vitro model with high-throughput, high-fidelity, and high efficacy. We hereby report a pipeline of establishing pan-cancer patient-derived 3DB (PT-3DB) models with personalized drug sensitivity results in 148 patients from multiple medical centers. Methods: Tumor tissues of 148 patients were collected with informed consent at 4 medical centers in Beijing, Hangzhou and Ningbo from 2022-12 to 2023-12. Tumors wer

APA, Harvard, Vancouver, ISO, and other styles

19

Fan, Caiyun, Wenbin Lu, Rui Song, and Yong Zhou. "Concordance-assisted learning for estimating optimal individualized treatment regimes." Journal of the Royal Statistical Society: Series B (Statistical Methodology) 79, no. 5 (2016): 1565–82. http://dx.doi.org/10.1111/rssb.12216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Huang, Xuelin, Jing Ning, and Abdus S. Wahed. "Optimization of individualized dynamic treatment regimes for recurrent diseases." Statistics in Medicine 33, no. 14 (2014): 2363–78. http://dx.doi.org/10.1002/sim.6104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wu, Chi-Shin, Albert C. Yang, Shu-Sen Chang, et al. "Validation of Machine Learning-Based Individualized Treatment for Depressive Disorder Using Target Trial Emulation." Journal of Personalized Medicine 11, no. 12 (2021): 1316. http://dx.doi.org/10.3390/jpm11121316.

Full text

Abstract:

This study aims to develop and validate the use of machine learning-based prediction models to select individualized pharmacological treatment for patients with depressive disorder. This study used data from Taiwan’s National Health Insurance Research Database. Patients with incident depressive disorders were included in this study. The study outcome was treatment failure, which was defined as psychiatric hospitalization, self-harm hospitalization, emergency visits, or treatment change. Prediction models based on the Super Learner ensemble were trained separately for the initial and the next-s

APA, Harvard, Vancouver, ISO, and other styles

22

García-Layana, Alfredo, Marta S. Figueroa, Luis Arias, et al. "Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration." Journal of Ophthalmology 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/412903.

Full text

Abstract:

Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that “tre

APA, Harvard, Vancouver, ISO, and other styles

23

Pazos, Montserrat, Stephan Schönecker, Daniel Reitz, et al. "Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer." Breast Care 13, no. 4 (2018): 285–91. http://dx.doi.org/10.1159/000488189.

Full text

Abstract:

Radiation therapy (RT) for breast cancer has dramatically changed over the past years, leading to individualized risk-adapted treatment strategies. Historically, the choice of RT regimen was limited to conventional fractionation protocols using standard tangential fields. Nowadays, technological and technical improvements in modern RT have added a variety of other RT modalities, different fractionation schedules, and individualised treatment volumes to the portfolio of breast RT. This review aims to give a short overview on the main topics which have recently found their way into clinical prac

APA, Harvard, Vancouver, ISO, and other styles

24

Shvartsur, Anna, Hermes Garban, and Benjamin Bonavida. "Overexpression of Raf Kinase Inhibitor Protein (RKIP) in Multiple Myeloma and Its Molecular Signature." Blood 128, no. 22 (2016): 5673. http://dx.doi.org/10.1182/blood.v128.22.5673.5673.

Full text

Abstract:

Abstract Multiple myeloma (MM) is a clonal plasma-cell neoplastic disorder arising from an indolent premalignant disease known as monoclonal gammopathy of undetermined significance (MGUS) that can evolve to asymptomatic pre-MM and later to symptomatic MM. MM is a biologically complex heterogeneous disease reflected by its variable clinical responses of patients receiving the same treatment. Therefore, a molecular identification of stage-specific biomarkers will support a more individualized precise diagnostic/prognostic approach, an effective therapeutic regime, and will assist in the identifi

APA, Harvard, Vancouver, ISO, and other styles

25

Volokhina, E., K. Wijnsma, R. van der Molen, et al. "Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment." Clinical Pharmacology & Therapeutics 102, no. 4 (2017): 671–78. http://dx.doi.org/10.1002/cpt.686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Liu, Xing. "Mechanisms and Clinical Management of Cancer-Associated Thromboembolism: Challenges and Advances." Theoretical and Natural Science 74, no. 1 (2024): 20–24. https://doi.org/10.54254/2753-8818/2024.la18834.

Full text

Abstract:

Cancer-associated thromboembolism (CAT) is a common and highly lethal complication in cancer patients. Tumors and their treatment increase the risk of thrombosis in patients. This article provides a systematic review of the mechanisms of CAT, the mechanism of action of anticoagulant drugs, and their use in the treatment of CAT. Low molecular heparin (LMWH) and new oral anticoagulants (DOACs) are the main therapeutic options recommended by current guidelines. However, in specific patient populations, it is important to individualize the treatment regimen. Recurrent thrombotic and bleeding compl

APA, Harvard, Vancouver, ISO, and other styles

27

Denic, Kristina Zoran, Sibylle Neuhoff, Joel Reid, and Rachel Kudget. "Abstract A140: A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients." Molecular Cancer Therapeutics 22, no. 12_Supplement (2023): A140. http://dx.doi.org/10.1158/1535-7163.targ-23-a140.

Full text

Abstract:

Abstract Introduction: Irinotecan is an inhibitor of the topoisomerase I enzyme that is essential in DNA transcription, replication, and repair. It is considered a “backbone” regime in colorectal cancer in adults and in pediatric gliomas to which other antineoplastic agents are added to improve the outcome. It is used as well in the treatment of many other types of adult and pediatric cancers. Irinotecan acts as a prodrug of SN-38 which has approximately 100-1000-fold greater cytotoxic activity. The metabolic and pharmacokinetic behavior of irinotecan is very complex and currently not complete

APA, Harvard, Vancouver, ISO, and other styles

28

Zhang, Haixiang, Jian Huang, and Liuquan Sun. "A rank-based approach to estimating monotone individualized two treatment regimes." Computational Statistics & Data Analysis 151 (November 2020): 107015. http://dx.doi.org/10.1016/j.csda.2020.107015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Rich, M. L., U. Khan, C. Zeng, et al. "Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications." International Journal of Tuberculosis and Lung Disease 27, no. 6 (2023): 451–57. http://dx.doi.org/10.5588/ijtld.22.0613.

Full text

Abstract:

BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.OBJECTIVES: To report end-of-treatment outcomes for MDR/RR-TB patients from a 2015–2018 multi-country cohort that received a regimen consistent with current 2022 WHO updated recommendations and describe the complexities of comparing regimens.METHODS: We analyzed a subset of participants from the endTB Observational Study who initiated a longer MDR/RR-TB regimen that was consistent with subsequent 2022 WHO guidance on regimen

APA, Harvard, Vancouver, ISO, and other styles

30

Procházka, Vít K., Štěpánka Matuštíková, Tomáš Fürst, et al. "Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients." Blood 136, Supplement 1 (2020): 20–21. http://dx.doi.org/10.1182/blood-2020-139830.

Full text

Abstract:

Background: Twenty percent of patients (pts) with high-tumor burden follicular lymphoma (FL) develop progression/relapse of disease within 24 months of frontline immune-chemotherapy (POD24). Those ultra-high-risk cases are at 50% risk of dying within 5-years since the POD event. Unmet need is to identify such pts at the time of initial treatment. The traditional approach used for building predictive scores (such as FLIPI, PRIMA-PI) is multivariable logistic regression (LR). LR is the tool of choice in case of many predictors (continuous or categorical) and a single binary (yes/no) outcome. Bay

APA, Harvard, Vancouver, ISO, and other styles

31

Gorodnova, T. V., A. P. Sokolenko, Kh B. Kotiv, et al. "Acquired Platinum Resistance of BRCA1-associated Ovarian Cancer after Neoadjuvant Chemotherapy." Doctor.Ru 21, no. 5 (2022): 87–91. http://dx.doi.org/10.31550/1727-2378-2022-21-5-87-91.

Full text

Abstract:

Objective of the Paper: To individualise the treatment programme for patients with advanced BRCA-associated ovarian cancer. Key points. Ovarian cancer is a highly aggressive disease characterized by low overall survival rates. The search for molecular markers, predictors of the effectiveness of drug therapy, is an urgent area of research. The article describes a clinical case of a fundamentally new approach to the combined treatment of a patient with BRCA1-associated advanced ovarian cancer. Conclusion. Molecular testing proved tumor resistance, which evolved during neoadjuvant therapy, so adj

APA, Harvard, Vancouver, ISO, and other styles

32

Verboven, Lennert, Steven Callens, John Black, et al. "A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis." PLOS ONE 19, no. 9 (2024): e0306101. http://dx.doi.org/10.1371/journal.pone.0306101.

Full text

Abstract:

Background Rifampicin resistant tuberculosis remains a global health problem with almost half a million new cases annually. In high-income countries patients empirically start a standardized treatment regimen, followed by an individualized regimen guided by drug susceptibility test (DST) results. In most settings, DST information is not available or is limited to isoniazid and fluoroquinolones. Whole genome sequencing could more accurately guide individualized treatment as the full drug resistance profile is obtained with a single test. Whole genome sequencing has not reached its full potentia

APA, Harvard, Vancouver, ISO, and other styles

33

Shevchenko, O. S., I. M. Kalmykova, M. F. Novohatska, O. V. Shyrapova, and O. O. Pogorelova. "Analysis of the effectiveness of individualized treatment regimens for nontuberculous mycobacterioses." Annals of Mechnikov Institute, no. 3 (October 1, 2017): 67–70. https://doi.org/10.5281/zenodo.1000148.

Full text

Abstract:

Despite the fact that in Ukraine, as well as worldwide the incidence of nontuberculous mycobacterioses is growing, in our country there are still no standardized protocols for their diagnosis and treatment, which makes it impossible to prescribe adequate chemotherapy and worsens the prognosis of treatment. We have retrospectively studied medical histories of 26 patients who were diagnosed with "pulmonary non-tuberculous mycobacteriosis" during 2014-2016. The diagnosis of "non-tuberculous mycobacteriosis" was established based on the growth of non-tuberculous mycobacteria (NTMB) in BACTEC syste

APA, Harvard, Vancouver, ISO, and other styles

34

Niesley, Michelle, Kathryn Doran, Nhu Huynh, and Marie Winters. "A model for coordinated delivery of individualized complementary and integrative medicine care for cancer survivors." Journal of Clinical Oncology 34, no. 3_suppl (2016): e286-e286. http://dx.doi.org/10.1200/jco.2016.34.3_suppl.e286.

Full text

Abstract:

e286 Background: Cancer survivors may experience both physical and psychosocial sequelae as a result of cancer treatment. Many patients consult either their oncologist or primary care physician for lifestyle interventions to address survivorship issues. While studies demonstrate complementary and integrative medicine (CIM) therapies may reduce the risk of both all-cause mortality and cancer-specific mortality by 50% (Frenkel M et al. Curr Oncol Rep. 2015 May;17(5):445), the most effective method to ensure compliance with individualized dietary counseling, exercise, or nutritional supplement in

APA, Harvard, Vancouver, ISO, and other styles

35

Virág, Marcell, Tamas Leiner, Mate Rottler, Klementina Ocskay, and Zsolt Molnar. "Individualized Hemodynamic Management in Sepsis." Journal of Personalized Medicine 11, no. 2 (2021): 157. http://dx.doi.org/10.3390/jpm11020157.

Full text

Abstract:

Hemodynamic optimization remains the cornerstone of resuscitation in the treatment of sepsis and septic shock. Delay or inadequate management will inevitably lead to hypoperfusion, tissue hypoxia or edema, and fluid overload, leading eventually to multiple organ failure, seriously affecting outcomes. According to a large international survey (FENICE study), physicians frequently use inadequate indices to guide fluid management in intensive care units. Goal-directed and “restrictive” infusion strategies have been recommended by guidelines over “liberal” approaches for several years. Unfortunate

APA, Harvard, Vancouver, ISO, and other styles

36

Chihara, Kazuo, Ekaterina Koledova, Akira Shimatsu, et al. "An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency." European Journal of Endocrinology 153, no. 1 (2005): 57–65. http://dx.doi.org/10.1530/eje.1.01936.

Full text

Abstract:

Objectives: To investigate the effects of growth hormone (GH) treatment, using a dose-adjustment regimen based on serum insulin-like growth factor (IGF)-I concentrations, in adult Japanese hypopituitary patients with GH deficiency. Study design: Japanese patients who had initially been administered GH (n = 31) or placebo (n = 28) in a 24-week double-blind study received individualized GH treatment in an open-label study for 48 weeks. Body composition from dual-energy X-ray absorptiometry (DXA) and serum IGF-I, IGF-binding protein 3 (IGFBP-3) and lipid levels were determined centrally. Results:

APA, Harvard, Vancouver, ISO, and other styles

37

Yang, Chin-Yi, Ja-Hon Lin, and Chien-Ming Chen. "Optical Coherence Tomography as a Diagnosis-Assisted Tool for Guiding the Treatment of Melasma: A Case Series Study." Diagnostics 14, no. 18 (2024): 2083. http://dx.doi.org/10.3390/diagnostics14182083.

Full text

Abstract:

Background/Objectives: Multiple underlying pathomechanisms may lead to melasma, but there has been no report on the use of optical coherence tomography (OCT) to reveal specific pathomechanisms in individual patients and provide individualized treatments accordingly. Using real-time OCT images, we studied the pathomechanisms of melasma in 12 female patients and the effects of individualized treatments. Methods: Patients were divided into good and bad improved groups according to the improvement in hyperpigmentation at month 4. Results: In the bad improved group, all melanin or confetti melanin

APA, Harvard, Vancouver, ISO, and other styles

38

Lytvynenko, N. A., M. V. Pogrebna, Yu O. Senko, L. M. Protsyk, S. P. Korotchenko, and R. L. Liubevych. "Treatment of MDR-TB/HIV/CMV patients under individualized regimes of antimycobacterial therapy." Infusion & Chemotherapy, no. 4 (December 28, 2022): 52–58. http://dx.doi.org/10.32902/2663-0338-2022-4-52-58.

Full text

Abstract:

BACKGROUND. Often in practice there are combinations of several diseases, or tuberculosis of the respiratory organs develops against the background of various comorbidities, including HIV. OBJECTIVE. To demonstrate best clinical practices for selecting the optimal individualized treatment regimen (ITR) in a patient with multidrug-resistant tuberculosis (MDR-TB) associated with HIV in the setting of severe immunosuppression and complicated by poor tolerability. MATERIALS AND METHODS. Presented clinical analysis of newly diagnosed generalized MDR-TB associated with HIV, treated for I

APA, Harvard, Vancouver, ISO, and other styles

39

Spoon, Kelly, Joshua Beemer, John C. Whitmer, et al. "Random Forests for Evaluating Pedagogy and Informing Personalized Learning." Journal of Educational Data Mining 8, no. 2 (2016): 20–50. https://doi.org/10.5281/zenodo.3554596.

Full text

Abstract:

Random forests are presented as an analytics foundation for educational data mining tasks. The focus is on course- and program-level analytics including evaluating pedagogical approaches and interventions and identifying and characterizing at-risk students. As part of this development, the concept of individualized treatment effects (ITE) is introduced as a method to provide personalized feedback to students. The ITE quantifies the effectiveness of intervention and/or instructional regimes for a particular student based on institutional student information and performance data. The proposed ra

APA, Harvard, Vancouver, ISO, and other styles

40

Paul, Christer, Henrik Green, Ingrid Jakobsen Falk, et al. "Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML." Blood 114, no. 22 (2009): 2648. http://dx.doi.org/10.1182/blood.v114.22.2648.2648.

Full text

Abstract:

Abstract Abstract 2648 Poster Board II-624 Background: Multidrug resistance and expression of the ATP-dependent drug transporting protein ABCB1 is a clinically relevant problem in the treatment of acute myeloid leukaemia. Several single nucleotide polymorphisms (SNPs) in the ABCB1 have been associated with altered P-glycoprotein expression and phenotype. These SNPs might influence the clinical outcome in AML and predict individual differences in response to therapy with ABCB1 substrates. Aims: To investigate the impact of the ABCB1 SNPs in exon 11, 12, 21 and 26 on treatment response, survival

APA, Harvard, Vancouver, ISO, and other styles

41

Bucheeri, Mohamed Abdulla Ghuloom Abdulla, Marion Elligsen, Philip W. Lam, Nick Daneman, and Derek MacFadden. "A sepsis treatment algorithm to improve early antibiotic de-escalation while maintaining adequacy of coverage (Early-IDEAS): A prospective observational study." PLOS ONE 18, no. 12 (2023): e0295908. http://dx.doi.org/10.1371/journal.pone.0295908.

Full text

Abstract:

Background Empiric antibiotic treatment selection should provide adequate coverage for potential pathogens while minimizing unnecessary broad-spectrum antibiotic use. We sought to pilot a sepsis treatment algorithm to individualize antibiotic recommendations, and thereby improve early antibiotic de-escalation while maintaining adequacy of coverage (Early-IDEAS). Methods In this observational study, the Early-IDEAS decision support algorithm was derived from previous Gram- negative and Gram-positive prediction rules and models along with local guidelines, and then applied to prospectively ident

APA, Harvard, Vancouver, ISO, and other styles

42

Abidi, Syed, Jay Achar, Mourtala Mohamed Assao Neino, et al. "Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis." European Respiratory Journal 55, no. 3 (2019): 1901467. http://dx.doi.org/10.1183/13993003.01467-2019.

Full text

Abstract:

We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9–12 months (the “shorter regimen”) and individualised regimens of ≥20 months (“longer regimens”).We collected individual patient data from observational studies identified through systematic reviews and a public call for data. We included patients meeting WHO eligibility criteria for the shorter regimen: not previously treated with second-line drugs, and with fluoroquinolone- and second-li

APA, Harvard, Vancouver, ISO, and other styles

43

Zhdanova, Elena, Olga Goncharova, Hayk Davtyan, et al. "9-12 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan." Journal of Infection in Developing Countries 15, no. 09.1 (2021): 66S—74S. http://dx.doi.org/10.3855/jidc.13757.

Full text

Abstract:

Introduction: MDR/RR-TB is a growing problem in Kyrgyzstan. In 2005, the country introduced standard or individualized treatment for 20-24 months. Because of poor treatment outcomes, in 2017 a short treatment with strict eligibility criteria was introduced. The aim of this study was to compare characteristics and treatment outcomes of MDR/RR-TB patients receiving short (9-12 months) treatment in 2017 with those receiving standard or individualized (20-24 months) treatment in 2016/2017. Methodology: A comparative cohort study using routine programmatic data. Characteristics, sputum cultur

APA, Harvard, Vancouver, ISO, and other styles

44

Symonds, Lynn K., and Stacey A. Cohen. "Use of perioperative chemotherapy in colorectal cancer metastatic to the liver." Gastroenterology Report 7, no. 5 (2019): 301–11. http://dx.doi.org/10.1093/gastro/goz035.

Full text

Abstract:

Abstract A curative-intent approach may improve survival in carefully selected patients with oligometastatic colorectal cancer. Aggressive treatments are most frequently administered to patients with isolated liver metastasis, though they may be judiciously considered for other sites of metastasis. To be considered for curative intent with surgery, patients must have disease that can be definitively treated while leaving a sufficient functional liver remnant. Neoadjuvant chemotherapy may be used for upfront resectable disease as a test of tumor biology and/or for upfront unresectable disease t

APA, Harvard, Vancouver, ISO, and other styles

45

Logan, Brent R., Rodney Sparapani, Robert E. McCulloch, and Purushottam W. Laud. "Decision making and uncertainty quantification for individualized treatments using Bayesian Additive Regression Trees." Statistical Methods in Medical Research 28, no. 4 (2017): 1079–93. http://dx.doi.org/10.1177/0962280217746191.

Full text

Abstract:

Individualized treatment rules can improve health outcomes by recognizing that patients may respond differently to treatment and assigning therapy with the most desirable predicted outcome for each individual. Flexible and efficient prediction models are desired as a basis for such individualized treatment rules to handle potentially complex interactions between patient factors and treatment. Modern Bayesian semiparametric and nonparametric regression models provide an attractive avenue in this regard as these allow natural posterior uncertainty quantification of patient specific treatment dec

APA, Harvard, Vancouver, ISO, and other styles

46

Wajnrajch, M. P., J. Hey-Hadavi, and N. Rajicic. "P26 An individualized, target-driven treatment regimen for children with idiopathic short stature (ISS)." Growth Hormone & IGF Research 20 (January 2010): S49. http://dx.doi.org/10.1016/s1096-6374(10)70126-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Delage, Gilles, Lucie Desautels, Sylvie Legault, et al. "Individualized Aminoglycoside Dosage Regimens in Patients with Cystic Fibrosis." Drug Intelligence & Clinical Pharmacy 22, no. 5 (1988): 386–89. http://dx.doi.org/10.1177/106002808802200504.

Full text

Abstract:

Individualized dosage regimens have recently been recommended for patients treated with aminoglycoside antibiotics. We have developed a calculator-based program for our patients with cystic fibrosis and have studied 93 courses of intravenous aminoglycoside treatment, comparing predicted and measured values in 45 courses. Pharmacokinetic parameters differed notably among subjects: This was reflected by widely variable total daily aminglycoside dosage requirements. The mean daily dosage requirements (± SD) for tobramycin (62 treatment courses) was 13.0 ± 3.74 mg/kg, and for gentamicin (26 treatm

APA, Harvard, Vancouver, ISO, and other styles

48

Skaarud, Kristin J., Marianne J. Hjermstad, Asta Bye, et al. "No Effect of Individualized Nutrition on Quality of Life, Acute Graft-Versus-Host Disease or Oral Mucositis after Allogeneic Stem Cell Transplantation: A Randomized Controlled Trial." Blood 128, no. 22 (2016): 2211. http://dx.doi.org/10.1182/blood.v128.22.2211.2211.

Full text

Abstract:

Abstract Introduction: Patients with hematological cancers treated with allogeneic stem cell transplantation (allo-SCT) after myeloablative conditioning are at risk of malnutrition due to inadequate energy intake. This may cause or contribute to adverse outcomes. The best way to prevent and treat malnutrition and optimize nutritional status in these patients, remains unknown. We therefore conducted a randomized controlled trial to examine the effect of an individualized nutritional intervention to optimize energy intake, on quality of life (QoL), severe acute graft-versus-host disease (aGVHD)

APA, Harvard, Vancouver, ISO, and other styles

49

T.F., Tatarchuk, Zakharenko N.F., Reheda S.I., and Kvasha T.I. "Algorithms for prescribing menopausal hormone therapy in different periods of menopause." REPRODUCTIVE ENDOCRINOLOGY, no. 66 (August 10, 2022): 68–70. https://doi.org/10.18370/2309-4117.2022.66.68-70.

Full text

Abstract:

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. MHT, initiated in women during the “therapeutic window” to relieve symptoms of estrogens deficiency and prevent or treat osteoporosis, is the only intervention that reduces the risk of cardiovascular diseases and diabetes in healthy middle-aged women. MHT must be individualized and adapted; that is, a differentiated selection of therapy should be carried out, considering the woman’s health status and her comorbidities, as well as the MHT regime

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Jiaying, David A. Solomon, Nancy Ann Oberheim Bush, et al. "CTNI-49. PRECISION MEDICINE CLINICAL TRIAL FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA." Neuro-Oncology 26, Supplement_8 (2024): viii107. http://dx.doi.org/10.1093/neuonc/noae165.0416.

Full text

Abstract:

Abstract Salvage therapies for recurrent glioblastoma (rGBM) have limited efficacy, with median overall survival of 9 months (OS-9) and 6-month progression-free survival (PFS-6) of 10-25%. Given GBM’s molecular heterogeneity, targeting a single molecular abnormality in isolation has consistently failed as a strategy, and precision combination approaches are needed. An initial 15-patient cohort evaluated the feasibility and safety of treating patients with rGBM with an individualized treatment regimen; we added a second 15-patient expansion cohort to improve the power of preliminary efficacy as

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!